Tuberous Sclerosis Complex (TSC) clinical management is evolving rapidly through advanced genomic tools. A significant new study demonstrates that exome sequencing in TSC can identify additional pathogenic variants in roughly 3.6% of individuals. These variants often involve genes associated with epilepsy and various neurodevelopmental disorders. Consequently, clinicians may need to look beyond the standard TSC1 and TSC2 mutations to provide comprehensive care.

Researchers performed exome sequencing and SNP array analysis on a cohort of 224 individuals with TSC. They followed strict ACMG guidelines to interpret the genetic results. Furthermore, the findings revealed that eight participants carried at least one secondary pathogenic variant. These variants increased the risk for intellectual disability and treatment-resistant epilepsy. Importantly, 44% of these patients qualified for direct targeted therapy, such as specific antiseizure medications or gene-based interventions.

Clinical Impact of Exome Sequencing in TSC

The knowledge of these additional conditions significantly informs clinical surveillance and prognosis. Moreover, TSC manifestations often mask second neurodevelopmental disorders, leading to potential diagnostic delays. Therefore, broader testing ensures that families receive accurate recurrence risk assessments. Additionally, this approach supports the ongoing shift toward precision medicine in pediatric neurology.

Ultimately, identifying these hidden variants allows for optimized treatment pathways. Knowing the full genetic profile helps in selecting the most effective medications for seizure control. This research underscores why broader genomic screening might be warranted for complex cases where symptoms exceed typical TSC expectations.

Frequently Asked Questions

How often do TSC patients have additional pathogenic variants?

According to recent research, approximately 3.6% of individuals with TSC carry additional pathogenic variants in genes related to epilepsy or other neurodevelopmental disorders.

Why should clinicians consider testing beyond the TSC1 and TSC2 genes?

Broad testing is beneficial because TSC symptoms can overlap with or mask other genetic conditions. Identifying these variants can lead to targeted therapies and more accurate genetic counseling for families.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Farach LS et al. Exome Sequencing Identifies Additional Pathogenic Variants in Neurodevelopmental Genes in 3.6% of Individuals with Tuberous Sclerosis Complex. Genet Med. 2026 Apr 15. doi: undefined. PMID: 41988793.


2. Northrup H et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243-254.


3. de Vries PJ et al. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist. Pediatr Neurol. 2015;52(1):25-35.